Evidence map›Paper›PMID 29594234›Full record

ArticleClinical and translational radiation oncology2017

Strong radioprotective FGF1 signaling down-regulates proliferative and metastatic capabilities of the angiosarcoma cell line, ISOS-1, through the dual inhibition of EGFR and VEGFR pathways.

Taichi Miura, Mayumi Fujita, Mitsuko Kawano, Kaori Imadome, Takeshi Yasuda, Shoko Nishihara, Toru Imamura, Mikio Masuzawa, Takashi Imai, Fumiaki Nakayama

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Taichi MiuraNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Mayumi FujitaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Mitsuko KawanoNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Kaori ImadomeNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Takeshi YasudaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Shoko NishiharaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Toru ImamuraNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Mikio MasuzawaDepartment of Molecular Diagnostics, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.
Takashi ImaiNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Fumiaki NakayamaNational Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
National Institutes for Quantum and Radiological Science and Technology · JPKitasato University · JPSoka University · JPTokyo University of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeAngiosarcoma is associated with a poor prognosis and is treated with radiotherapy. Although FGF1 is a potential radioprotector, the influence of FGF1 on the malignancy of angiosarcoma remains unknown. MATERIALS AND

methodsHighly stable FGF1 mutants, which exhibit stronger mitogenic activity than wild-type FGF1, were examined as strong radioprotectors and signaling agonists to clarify the effects of FGF1 on the murine angiosarcoma cell line ISOS-1.

resultsFGF1 mutants reduced colony formation by and the

conclusionThese results suggest that strong FGF1 signaling exerts not only radioprotective effects, but also inhibitory effects on proliferative and metastatic capacities of angiosarcoma through the dual inhibition of EGFR and VEGFR pathways.

Indexed as

AngiosarcomaEGFRFGF1MetastasisRadioprotectorVEGFR

Identifiers

PMID29594234
PMCPMC5862641
OpenAlexW2767159136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.